CN114145716B - Human body efficacy quantitative evaluation method for blue light protection and application thereof - Google Patents
Human body efficacy quantitative evaluation method for blue light protection and application thereof Download PDFInfo
- Publication number
- CN114145716B CN114145716B CN202111484743.7A CN202111484743A CN114145716B CN 114145716 B CN114145716 B CN 114145716B CN 202111484743 A CN202111484743 A CN 202111484743A CN 114145716 B CN114145716 B CN 114145716B
- Authority
- CN
- China
- Prior art keywords
- blue light
- area
- index
- skin
- light protection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 32
- 238000011158 quantitative evaluation Methods 0.000 title claims abstract description 22
- 238000012360 testing method Methods 0.000 claims abstract description 77
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000011248 coating agent Substances 0.000 claims abstract description 17
- 238000000576 coating method Methods 0.000 claims abstract description 17
- 238000005259 measurement Methods 0.000 claims description 5
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 claims description 5
- 230000037311 normal skin Effects 0.000 claims description 5
- 239000001043 yellow dye Substances 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 abstract description 8
- 230000000007 visual effect Effects 0.000 abstract description 4
- 238000012827 research and development Methods 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 230000019612 pigmentation Effects 0.000 description 4
- 230000036555 skin type Effects 0.000 description 4
- 206010020112 Hirsutism Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010027145 Melanocytic naevus Diseases 0.000 description 3
- 208000007256 Nevus Diseases 0.000 description 3
- 206010034960 Photophobia Diseases 0.000 description 3
- 239000003470 adrenal cortex hormone Substances 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 208000013469 light sensitivity Diseases 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 238000005286 illumination Methods 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011252 protective cream Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/443—Evaluating skin constituents, e.g. elastin, melanin, water
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/10—Complex mathematical operations
- G06F17/11—Complex mathematical operations for solving equations, e.g. nonlinear equations, general mathematical optimization problems
Landscapes
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mathematical Physics (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Pure & Applied Mathematics (AREA)
- Mathematical Optimization (AREA)
- Mathematical Analysis (AREA)
- Computational Mathematics (AREA)
- Public Health (AREA)
- Operations Research (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Algebra (AREA)
- Biophysics (AREA)
- Databases & Information Systems (AREA)
- Software Systems (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a human body efficacy quantitative evaluation method for blue light protection and application thereof. The quantitative evaluation method for the human body efficacy of the blue light protection comprises the following steps: setting a test area, a control area and a standard area on skin to be tested, and measuring the melanin index, the brightness index and the skin yellow index of each area; coating a blue light protection sample in the test area; blue light irradiation is carried out on the test area and the control area, and the melanin index, the brightness index and the skin yellow index of the skin of the test area, the control area and the standard area are respectively measured; and calculating a blue light protection index. The invention provides the human body efficacy quantitative evaluation method for the blue light protection, overcomes the defect of the blue light protection efficacy evaluation method, provides a more visual evaluation method for a blue light protection sample, and has important significance for research and development of the blue light protection sample.
Description
Technical Field
The invention relates to the technical cosmetic skin science field, in particular to a human body efficacy quantitative evaluation method for blue light protection and application thereof.
Background
Blue light is visible light commonly existing in daily life, has a wavelength of 400-500nm, and belongs to high-energy visible light. The influence of blue light on human body is various, and can damage the visual system of human body and influence the biological rhythm of human body. Research shows that high-energy blue light can cause serious loss to human skin, and can cause macula, freckle, accelerated skin aging, skin allergy and influence sleep quality. Blue light irradiation can cause obvious pigmentation on the skin of people with dark complexion, and has slight influence on people with light complexion, especially the skin pigmentation of people with Chinese complexion is seriously influenced. Electronic products are becoming more and more abundant in today's society, however, blue light intensity of these electronic products is very high, such as computers, televisions, mobile phones, etc.
Currently, the market potential of a protective sample for blue light is huge, however, an effective protective sample is lacking, and one important reason is that a blue light protection efficacy evaluation method is lacking. Therefore, the human body efficacy evaluation method for constructing the blue light protection based on the skin characteristics of Chinese people has great market potential.
Disclosure of Invention
The invention aims to provide a human body efficacy quantitative evaluation method for blue light protection, which aims to solve the technical problem of lack of the efficacy evaluation method for blue light protection.
In order to achieve the above purpose, the invention provides a human body efficacy quantitative evaluation method for blue light protection, which comprises the following steps:
setting a test area, a control area and a standard area on skin to be tested, and measuring the melanin index, the brightness index and the skin yellow dye index of each area;
step two, coating a blue light protection sample in the test area;
step three, blue light irradiation is carried out on the test area and the control area, and the melanin index M, the brightness index L and the skin yellow index b of the skin of the test area, the control area and the standard area are respectively measured; repeating the blue light irradiation and the index measurement for a plurality of times according to the same time interval, and recording data;
step four, calculating a blue light protection index according to the data obtained in the step three, wherein a calculation formula comprises:
formula one:or (b)
Formula II:
wherein,
in the formula, BPF is a blue light protection index; c (C) i Is the difference of the skin melanin indexes of the control area and the standard area, or the difference of the brightness indexes of the control area and the standard area, or the difference of the ITA degree indexes of the control area and the standard area; ITA ° is used to characterize skin tone;is C i Is the average value of (2); p (P) i The difference value is the skin melanin index of the test area and the standard area, or the brightness index of the test area and the standard area, or the ITA degree index of the test area and the standard area; />Is P i Is the average value of (2);T i for test days, < > Suo->Is T i Is the average value of (2); n is the number of days of data measured, i is an integer of 1:n; k (k) control Slope, k of straight line fitted to skin color change value of control region and time product The slope of the straight line is fitted to the test area skin color change value with time.
Further, the calculation formula of ITA DEG is:l is the brightness index and b is the skin yellow index.
Further, the method comprises a fifth step, specifically: repeating the first to fourth steps, performing a plurality of parallel tests, calculating the mean value and the blue light protection index, and taking the blue light protection index calculated by the data mean value as the efficacy quantitative evaluation standard of the blue light protection.
Further, the proportion of the blue light irradiated light source with the wavelength within the wave band of 400-700 nm is more than or equal to 50%.
Further, the proportion of the blue light irradiated light source in a wave band with the wavelength smaller than 400nm is smaller than or equal to 2.5%.
Further, the area of the test area is 4-20 em 2 。
Further, the coating weight of the blue light protection sample in the test area is 2-5 mg/cm 2 。
Further, after the blue light protection sample is coated, the test area waits for at least 15 minutes and then irradiates with blue light.
Further, the dose of blue light irradiation is less than or equal to the maximum blue light irradiation dose.
Further, the maximum blue light irradiation dose is derived from: the maximum blue light irradiation dose of normal skin was reduced by 1.25 times based on the minimum irradiation dose or the minimum irradiation time at which the skin appears as black spots, expressed as MBD.
Further, in the third step, the time interval is 1-2 days.
Further, in the fourth step, n in the formula is 4 to 10.
Further, the skin to be detected is local skin of the detector.
Further, the inspector meets the following requirements:
(1) The number of the detected persons is at least 30;
(2) Selecting 18-60 years old healthy volunteer testers, and enabling men and women to do so;
(3) No medicine affecting the light sensitivity is used in the past history of no light-sensitive disease in 6 months before the test;
(4) According to Fitzpatrick skin typing, the skin types of the detector are more than type III, wherein the types III and IV of the skin are not less than 5 persons;
(5) Skin at the tested part should be free of pigmentation, inflammation, scar, nevus pigmentosus and hirsutism;
(6) Pregnancy, lactation, oral or external anti-inflammatory drugs, for example: the corticosteroid hormone, or similar subjects who have received a similar trial in the last month, should be excluded from the test subjects.
The test and control areas of the present invention should not receive a dose of blue light higher than the maximum blue light dose MBD.
The invention also provides application of the quantitative evaluation method of the human body efficacy of the blue light protection in the detection of the blue light protection of cosmetics.
The invention has the beneficial effects that:
the invention provides the human body efficacy quantitative evaluation method for the blue light protection, overcomes the defect of the blue light protection efficacy evaluation method, provides a more visual evaluation method for a blue light protection sample, and has important significance for research and development of the blue light protection sample.
Drawings
FIG. 1 is a line graph with Delta M as Y axis and days as X axis for example 1 of the present invention.
FIG. 2 is a line graph with Delta L on the Y axis and days on the X axis for example 1 of the present invention.
FIG. 3 is a line graph of example 1 of the present invention with Delta ITA DEG on the Y axis and days on the X axis.
FIG. 4 is a line graph with Delta M on the Y axis and days on the X axis for example 2 of the present invention.
FIG. 5 is a line graph with Delta L on the Y axis and days on the X axis for example 2 of the present invention.
FIG. 6 is a line graph of example 2 of the present invention with Delta ITA as Y axis and days as X axis
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the present invention more apparent, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention. Unless otherwise defined, technical or scientific terms used herein should be given the ordinary meaning as understood by one of ordinary skill in the art to which this invention belongs. As used herein, the word "comprising" and the like means that elements or items preceding the word are included in the element or item listed after the word and equivalents thereof without precluding other elements or items.
The embodiment of the invention provides a human body efficacy quantitative evaluation method for blue light protection, which comprises the following steps:
setting a test area, a control area and a standard area on skin to be tested, and measuring the melanin index, the brightness index and the skin yellow dye index of each area;
step two, coating a blue light protection sample in the test area;
step three, blue light irradiation is carried out on the test area and the control area, and the melanin index M, the brightness index L and the skin yellow index b of the skin of the test area, the control area and the standard area are respectively measured; repeating the blue light irradiation and the index measurement for a plurality of times according to the same time interval, and recording data;
step four, calculating a blue light protection index according to the data obtained in the step three, wherein a calculation formula comprises:
formula one:or (b)
Formula II:
wherein,
in the formula, BPF is a blue light protection index; c (C) i The difference value is the difference value between the skin color index of the control area and the skin color index of the standard area, namely the difference value between the skin melanin index M value of the control area and the M value of the standard area, or the difference value between the brightness index L value of the control area and the L value of the standard area, or the difference value between the ITA degree index of the control area and the ITA degree value of the standard area;is C i Is the average value of (2); p (P) i The difference value between the skin color index of the test area and the skin color index of the standard area is the difference value between the skin melanin index M value of the test area and the M value of the standard area, or the difference value between the brightness index L value of the test area and the L value of the standard area, or the difference value between the ITA degree index of the test area and the ITA degree value of the standard area; ITA ° is used to characterize skin tone; />Is P i Is the average value of (2); t (T) i For test days, < > Suo->Is the average value of Ti; n is the number of days of data measured, i is an integer of 1:n; k (k) control Slope, k of straight line fitted to skin color change value of control region and time product The slope of the straight line is fitted to the test area skin color change value with time.
In detail, the test area, the control area and the standard area in the invention are positioned adjacently, and the skin states are similar. The processing modes of the three are different in the method: the test area is coated with a product and irradiated with light; control area, not coating product and only illuminating; standard area: the product is not coated and is not shiny.
For example, the standard area may be selected from the area under the scapula when the tester is in prone position, and the area immediately adjacent to the test area and the control area, the skin is flat, and the skin color and texture are uniform.
The inventors have found during the course of the study that document "Skin colour typology and suntanning pathways" reports that ITA ° (Individual Typologic Angle) is used to characterize skin tone, and that skin color can be accurately reflected on the level of skin brightness index L value and Huang Ranzhi number b value, the greater the value, the brighter the skin. The calculation formula of ITA DEG is:l is the brightness index and b is the skin yellow index. The present invention uses this ita° to characterize skin tone.
In some embodiments, the method may further include a step five, specifically: repeating the first to fourth steps, performing a plurality of parallel tests, calculating the mean value and the blue light protection index, and taking the blue light protection index calculated by the data mean value as the efficacy quantitative evaluation standard of the blue light protection.
In some embodiments, the blue light irradiates the light source with a proportion of wavelengths in the 400-700 nm band of greater than or equal to 50%; for example, 50%, 60%, 70%, 80% may be used. The proportion of the light source irradiated by the blue light in a wave band with the wavelength less than 400nm is less than or equal to 2.5 percent; for example, the content may be 2.5%, 2.0%, 1.5%, 1.0%.
In an embodiment, the area of the test area coated with the sample is not less than 4cm 2 The coating weight was 2mg/cm 2 Wait at least 15 minutes after coating uniformity.
In some embodiments, the test area is 4-20 cm 2 . In other words, the blue light protection sampleThe coating area of the product is 4-20 cm 2 . For example, the test area may be 4cm 2 、5cm 2 、7cm 2 、10cm 2 、12cm 2 、15cm 2 、18cm 2 Or 20cm 2 。
In some embodiments, the test area is blue-irradiated after waiting at least 15 minutes after coating the blue-protected sample.
In some embodiments, the coating amount of the blue light protection sample in the test area is 2-5 mg/cm 2 . Preferably, the coating amount of the blue light protection sample in the test area is 2mg/cm 2 。
In some embodiments, the dose of blue light illumination is less than or equal to the maximum blue light illumination dose. Further, the maximum blue light irradiation dose is derived from: the maximum blue light irradiation dose of normal skin was reduced by 1.25 times based on the minimum irradiation dose or the minimum irradiation time at which the skin appears as black spots, expressed as MBD.
In some embodiments, in step three, the time interval is 1-2 days; preferably, the time interval is 1 day. In the fourth step, n in the formula is 4-10; for example, n may be 4, 5, 6, 7, 8, 9, or 10.
The skin to be detected is local skin of a detector.
For example, the method for confirming the maximum blue light irradiation dose may be: selecting irradiation region on back or abdominal skin of the person to be tested, taking 6 points and using 50J/cm 2 、60J/cm 2 、75J/cm 2 、95J/cm 2 、120J/cm 2 、150J/cm 2 Respectively irradiating blue light of the substrate, and observing the substrate 2 hours after irradiation; the maximum blue light irradiation dose of normal skin was reduced by 1.25 times based on the minimum irradiation dose or the minimum irradiation time at which the skin appears as black spots, expressed as MBD.
For example, the inspector should meet the following requirements:
(1) The number of the detected persons is at least 30;
(2) Selecting 18-60 years old healthy volunteer testers, and enabling men and women to do so;
(3) No medicine affecting the light sensitivity is used in the past history of no light-sensitive disease in 6 months before the test;
(4) According to Fitzpatrick skin typing, the skin types of the detector are more than type III, wherein the types III and IV of the skin are not less than 5 persons;
(5) Skin at the tested part should be free of pigmentation, inflammation, scar, nevus pigmentosus and hirsutism;
(6) Pregnancy, lactation, oral or external anti-inflammatory drugs, for example: the corticosteroid hormone, or similar subjects who have received a similar trial in the last month, should be excluded from the test subjects.
In addition, the calculation formula of the blue light protection index is deduced by the following method; calculating slope k by least square method with time as X axis and difference between melanin index M, brightness index L or ITA degree of control region and standard region as Y axis control The method comprises the steps of carrying out a first treatment on the surface of the In the same way, the time is taken as the X axis, the difference value between the melanin index M, the brightness index L or the ITA degree of the test area and the standard area is taken as the Y axis, and the slope k is calculated by adopting a least square method product ；
Or,
wherein,
the invention has been tested several times in succession, and the invention will now be described in further detail with reference to a few test results, which are described in detail below in connection with specific examples.
Example 1
The embodiment provides a human body efficacy quantitative evaluation method for blue light protection.
The blue light source is: the relative proportion of 400-700 nm is not less than 50%, and the wave band with the wavelength less than 400nm is not more than 2.5%.
Test sample (i.e., protective sample): sample 1 was a corporate product protective cream (from the home made sample of Shanghai Fender detection technologies Co., ltd.).
The inspector meets the following requirements:
(1) The number of the detected persons is 35;
(2) Selecting 18-60 years old healthy volunteer testers, and enabling men and women to do so;
(3) No medicine affecting the light sensitivity is used in the past history of no light-sensitive disease in 6 months before the test;
(4) The skin type of the detected person is more than III type, wherein the III type and IV type skin are not less than 5 persons;
(5) Skin at the tested part should be free of pigmentation, inflammation, scar, nevus pigmentosus and hirsutism;
(6) Pregnancy, lactation, oral or external anti-inflammatory drugs, for example: the corticosteroid hormone, or similar subjects who have received a similar trial in the last month, should be excluded from the test subjects.
The dose of blue light irradiation should be confirmed before the inspector receives the blue light irradiation for 2 hours, and the specific operation is as follows;
determination of maximum blue light irradiation dose MBD: skin selection on the back of a person under testIrradiating the region with 50J/cm for 6 points 2 、60J/cm 2 、75J/cm 2 、95J/cm 2 、120J/cm 2 、150J/cm 2 Is observed 2 hours after irradiation. The minimum irradiation dose or the minimum irradiation time for the black spot of the skin is taken as a reference, and the maximum blue light irradiation dose which is reduced by 1.25 times is represented by MBD (MBD) of normal skin of the tester. The test and control areas should not receive more blue light than the maximum blue light dose MBD.
The quantitative evaluation method of the human body efficacy of the blue light protection comprises the following steps of testing each tester according to the following method:
step 1, the pre-marked area of the back of the testee is not lower than 4cm 2 A test area, a control area and a standard area corresponding to the test area, and measuring the melanin index M, the brightness index L and the skin yellow index b of each area;
step 2. Coating the sample in the test area with a coating weight of 2mg/cm 2 Coating uniformly with a latex finger stall and waiting for 15 minutes;
step 3, irradiating the test area and the control area by blue light, and measuring the melanin index M, the brightness index L and the skin yellow dye index b of the skin of the test area, the control area and the standard area; repeatedly performing irradiation and index measurement at 1 day intervals, and recording 5 groups of data;
step 4, calculating a blue light protection index through the following formula;
or:
wherein,
in the formula, BPF is blue light protection index, C i For the difference between the skin melanin index M, the brightness index L or the ITA deg. of the control area and the skin melanin index M, the brightness index L or the ITA deg. of the standard area, the ITA deg. can be calculated from L and b,is C i Is the average value of (2); p (P) i For the difference between the melanin index M, brightness index L or ITA DEG of the skin of the test area and the melanin index M, brightness index L or ITA DEG of the skin of the standard area,/>Is P i Is the average value of (2); t (T) i For test days, < > Suo->Is T i Is the average value of (2); n is the number of days of data measured, and i is an integer from 1 to n.
ITA ° is calculated by the following formula:ita° can accurately reflect the skin color at the level of the L value and the b value, and the larger the value thereof, the brighter the skin.
Step 5, repeating the above steps for parallel test, calculating the blue light protection index, and using the average number of the blue light protection indexes of multiple groups of parallel testsAs a human body efficacy quantitative evaluation standard for blue light protection.
The measurement results of the skin melanin index M, the brightness index L, and the skin tone index ITA ° in the present embodiment are shown in fig. 1 to 3; in the figure, control refers to the control area (uncoated sample group), product refers to the test area (coated sample group), day is the number of days. FIG. 1 is a line graph with Delta M (i.e., the amount of change in the melanin index M) on the Y-axis and days on the X-axis. FIG. 2 is a line graph with Delta L (i.e., the amount of change in the brightness index L) on the Y-axis and days on the X-axis. FIG. 3 is a line graph with Delta ITA DEG (i.e., the amount of change in ITA DEG) on the Y-axis and days on the X-axis.
Example 2
In this example, a test was conducted on a tester by the method of example 1, and specific data obtained are shown in table 1.
The detector: data number F024, gender: a male; age: age 58; skin type: III.
Table 1: distribution of Delta M values by inspector F024 at 5 time points of uncoated and coated sample groups
In table 1, M is the melanin index; delta M is the difference between the M of the test area and the standard area or the difference between the M of the control area and the standard area, and represents the variation of the melanin index M.
Plotting with Delta M as Y axis and days as X axis, as shown in FIG. 1, and calculating slope by the calculation formula of example 1 to obtain slope K1 of the control region, i.e. the non-smeared sample group, as 2.18; the slope of the test area, i.e. the smear sample group, was K2 of 2.01. Bpf=2.18/2.01=1.09 was calculated, see fig. 4.
Table 2: distribution of Delta L values by inspector F024 at 5 time points of uncoated and coated sample groups
In table 2, L is a brightness index; delta L is the difference between the L of the test area and the standard area or the difference between the L of the control area and the standard area, and represents the variation of L.
Plotting with Delta L as Y axis and days as X axis, as shown in FIG. 2, and calculating slope by the calculation formula of example 1 to obtain slope K2 of the control region, i.e. the non-smeared sample group, as-2.12; the slope K2 of the test area, i.e. the smear sample group, was-1.93. Bpf= -2.12/-1.93 = 1.10, see fig. 5.
Table 3: distribution of Delta ITA values by inspector F024 at 5 time points of uncoated and coated sample groups
In table 3, ITA ° is skin tone index; delta ITA DEG is the ITA DEG difference between the test area and the standard area or the ITA DEG difference between the control area and the standard area, and represents the variation of the ITA DEG.
Plotting with Delta ITA DEG as Y axis and days as X axis, as shown in FIG. 3, and calculating slope by the calculation formula of example 1 to obtain slope K1 of the control region, i.e. the non-smeared sample group, as-3.88; the slope K2 of the test area, i.e. the smear sample group, was-3.73. Bpf= -3.88/-3.73 = 1.04, see fig. 6.
Summarizing the results of the three groups of data to obtain:
table 4: slope (K) of individual F024 at 5 time points between sample and uncoated sample groups and BPF
| K | Sample group | Uncoated sample group | BPF |
| Delta M | 2.01 | 2.18 | 1.09 |
| Delta L | -1.93 | -2.12 | 1.10 |
| Delta ITA° | -3.73 | -3.88 | 1.04 |
Example 3
For sample 1 in example 1, 35 detectors (F001-F036, where F027 data were not accessed) were tested and the data are shown in table 5, table 5 including tables 5.1, 5.2 and 5.3, as a statistical description of the daily delta values for the product group and the control group.
TABLE 5.1
TABLE 5.2
TABLE 5.3
The average value and time in the data in Table 5 are fitted to linear equations, and the slope and BPF are calculated, and the results are shown in Table 6. Table 6 is the slope and BPF at delta M, delta L and delta ITA DEG for the product group and the control group.
TABLE 6
| K | Product | Control | BPF |
| Delta M | 0.63 | 1.12 | 1.77 |
| Delta L | -0.67 | -1.19 | 1.77 |
| Delta ITA° | -1.77 | -2.43 | 1.37 |
In summary, the method can effectively detect the blue light protection index of the protection sample, provides a more visual evaluation method for the blue light protection sample, and has important significance for the research and development of the blue light protection sample.
While embodiments of the present invention have been described in detail hereinabove, it will be apparent to those skilled in the art that various modifications and variations can be made to these embodiments. It is to be understood that such modifications and variations are within the scope and spirit of the present invention as set forth in the following claims. Moreover, the invention described herein is capable of other embodiments and of being practiced or of being carried out in various ways.
Claims (10)
1. The quantitative evaluation method for the human body efficacy of the blue light protection is characterized by comprising the following steps of:
setting a test area, a control area and a standard area on skin to be tested, and measuring the melanin index, the brightness index and the skin yellow dye index of each area;
step two, coating a blue light protection sample in the test area;
step three, carrying out blue light irradiation on the test area and the control area, and respectively measuring the melanin index, the brightness index and the skin yellow dye index of the skin of the test area, the control area and the standard area; repeating the blue light irradiation and the index measurement for a plurality of times according to the same time interval, and recording data;
step four, calculating a blue light protection index according to the data obtained in the step three, wherein a calculation formula comprises:
formula one:，
or (b)
Formula II:，
wherein,，/>，/>；
in the formula, BPF is a blue light protection index;is the difference of the skin melanin indexes of the control area and the standard area, or the difference of the brightness indexes of the control area and the standard area, or the difference of the ITA degree indexes of the control area and the standard area; ITA ° is used to characterize skin tone; />Is->Is the average value of (2); />The difference value is the skin melanin index of the test area and the standard area, or the brightness index of the test area and the standard area, or the ITA degree index of the test area and the standard area; />Is->Is the average value of (2); />For test days, < > Suo->Is->Is the average value of (2); n is the number of days of data measured, i is an integer from 1 to n; />Slope of straight line fitted to skin color change value and time for control region, +.>Slope of a straight line is fitted for the skin color change value of the test area and time;
the calculation formula of ITA DEG is:the method comprises the steps of carrying out a first treatment on the surface of the L is the brightness index and b is the skin yellow index.
2. The method for quantitatively evaluating the efficacy of a blue light protected human body according to claim 1, wherein the method comprises the following steps: repeating the first step to the fourth step, performing a plurality of parallel tests to obtain a plurality of blue light protection indexes, and taking the average value obtained by calculating the plurality of blue light protection indexes as a efficacy quantitative evaluation standard of blue light protection.
3. The quantitative evaluation method for human body efficacy of blue light protection according to claim 1, wherein the proportion of the wavelength of the light source irradiated by blue light in a wave band of 400-700 nm is greater than or equal to 50%; the proportion of the blue light irradiated light source in a wave band with the wavelength smaller than 400nm is smaller than or equal to 2.5%.
4. The quantitative evaluation method for human body efficacy of blue light protection according to claim 1, wherein the area of the test area is 4-20 cm 2 。
5. The quantitative evaluation method for human body efficacy of blue light protection according to claim 4, wherein the coating amount of the blue light protection sample is 2-5 mg/cm 2 。
6. The method for quantitatively evaluating the efficacy of a blue light protected human body according to any one of claims 1 to 5, wherein after coating the blue light protected sample, blue light irradiation is performed after waiting for at least 15 minutes.
7. The method for quantitatively evaluating the efficacy of blue light protection of a human body according to claim 1, wherein the dose of blue light irradiation is less than or equal to the maximum blue light irradiation dose;
the maximum blue light irradiation dose is derived from: the maximum blue light irradiation dose of normal skin is reduced by 1.25 times based on the minimum irradiation dose or the minimum irradiation time when the skin appears to be black spots.
8. The method for quantitatively evaluating the efficacy of a blue light protected human body according to claim 1, wherein in the third step, the time interval is 1-2 days.
9. The method for quantitatively evaluating the efficacy of a blue light shielding human body according to claim 1, wherein in the fourth step, n in the formula is 4-10.
10. Use of the human body efficacy quantitative evaluation method for blue light protection according to any one of claims 1 to 9 in blue light protection detection of cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111484743.7A CN114145716B (en) | 2021-12-07 | 2021-12-07 | Human body efficacy quantitative evaluation method for blue light protection and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111484743.7A CN114145716B (en) | 2021-12-07 | 2021-12-07 | Human body efficacy quantitative evaluation method for blue light protection and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114145716A CN114145716A (en) | 2022-03-08 |
| CN114145716B true CN114145716B (en) | 2024-02-09 |
Family
ID=80453288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111484743.7A Active CN114145716B (en) | 2021-12-07 | 2021-12-07 | Human body efficacy quantitative evaluation method for blue light protection and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114145716B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111787847A (en) * | 2018-02-26 | 2020-10-16 | 株式会社爱茉莉太平洋 | Skin change measuring device and method using blue light, and blue light irradiation device |
| KR20210091480A (en) * | 2020-01-14 | 2021-07-22 | (주)지에프씨생명과학 | Assessment method of protection efficacy of blue light in cosmetics |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100145886A1 (en) * | 2008-12-08 | 2010-06-10 | Conopco, Inc., D/B/A Unilever | Evaluation and Selection Process for Consumer Products |
-
2021
- 2021-12-07 CN CN202111484743.7A patent/CN114145716B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111787847A (en) * | 2018-02-26 | 2020-10-16 | 株式会社爱茉莉太平洋 | Skin change measuring device and method using blue light, and blue light irradiation device |
| KR20210091480A (en) * | 2020-01-14 | 2021-07-22 | (주)지에프씨생명과학 | Assessment method of protection efficacy of blue light in cosmetics |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114145716A (en) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koga et al. | Key point in dermoscopic differentiation between early nail apparatus melanoma and benign longitudinal melanonychia | |
| Flohil et al. | Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study | |
| Longo et al. | Classifying distinct basal cell carcinoma subtype by means of dermatoscopy and reflectance confocal microscopy | |
| McLean et al. | “Sunburn” freckles, café-au-lait macules, and other pigmented lesions of schoolchildren: The Vancouver Mole Study | |
| Darlington et al. | Longitudinal study of melanocytic nevi in adolescents | |
| Ramsay et al. | Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients | |
| Arendse et al. | Evaluation of biochemical markers associated with the development of husk scald and the use of diffuse reflectance NIR spectroscopy to predict husk scald in pomegranate fruit | |
| McCreath et al. | Use of Munsell color charts to measure skin tone objectively in nursing home residents at risk for pressure ulcer development | |
| Kvaskoff et al. | Solar elastosis and cutaneous melanoma: a site‐specific analysis | |
| Lee et al. | Burns objective scar scale (BOSS): validation of an objective measurement devices based burn scar scale panel | |
| Rubegni et al. | Melanocytic skin lesions and pregnancy: digital dermoscopy analysis | |
| Hallam et al. | A practical and objective approach to scar colour assessment | |
| Boyd et al. | Phenotypic variability among café-au-lait macules in neurofibromatosis type 1 | |
| Gankande et al. | Interpretation of the DermaLab Combo® pigmentation and vascularity measurements in burn scar assessment: an exploratory analysis | |
| CN114145716B (en) | Human body efficacy quantitative evaluation method for blue light protection and application thereof | |
| dos Santos Silva et al. | Overseas sun exposure, nevus counts, and premature skin aging in young English women: a population-based survey | |
| Deng et al. | Measuring vascularity of hypertrophic scars by dermoscopy: construct validity and predictive ability of scar thickness change | |
| JPH11506200A (en) | Method and apparatus for detecting and measuring conditions affecting color | |
| Scafide et al. | Reliability of tristimulus colourimetry in the assessment of cutaneous bruise colour | |
| Purswani et al. | Radiation-induced skin changes after breast or chest wall irradiation in patients with breast cancer and skin of color: a systematic review | |
| Gruber et al. | Sensitivity and specificity of self-examination for cutaneous malignant melanoma risk factors | |
| Nourbala et al. | The prevalence of hirsutism in adolescent girls in Yazd, Central Iran | |
| Yajima et al. | Spectrophotometric and tristimulus analysis of the colors of subcutaneous bleeding in living persons | |
| CN106442331B (en) | Method for testing waterproof capability of sun-proof product | |
| CN115381405A (en) | Detection system for nevus flammeus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |